FCPh MD - Arcturus Therapeutics Chief Officer
| ARCT Stock | USD 17.51 0.58 3.43% |
Executive
FCPh MD is Chief Officer of Arcturus Therapeutics Holdings
| Age | 68 |
| Address | 10628 Science Center Drive, San Diego, CA, United States, 92121 |
| Phone | 858 900 2660 |
| Web | https://arcturusrx.com |
Arcturus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1215) % which means that it has lost $0.1215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2312) %, meaning that it created substantial loss on money invested by shareholders. Arcturus Therapeutics' management efficiency ratios could be used to measure how well Arcturus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, Arcturus Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 450.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 38.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Jim MBA | Fate Therapeutics | N/A | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Ravi Upasani | Biomea Fusion | N/A | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Paul Shin | 89bio Inc | N/A | |
| Andrew Henry | Fate Therapeutics | 60 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| David JD | Akero Therapeutics | N/A | |
| Raju Prasad | Crispr Therapeutics AG | 40 | |
| Manmohan Singh | Beam Therapeutics | N/A | |
| Susan Kim | Crispr Therapeutics AG | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Amy MD | Beam Therapeutics | 60 | |
| Daniel Anderson | Crispr Therapeutics AG | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Uneek Mehra | 4D Molecular Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.12 |
Arcturus Therapeutics Leadership Team
Elected by the shareholders, the Arcturus Therapeutics' board of directors comprises two types of representatives: Arcturus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcturus. The board's role is to monitor Arcturus Therapeutics' management team and ensure that shareholders' interests are well served. Arcturus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcturus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roberta Duncan, Chief Officer | ||
| Lance Kurata, Chief Officer | ||
| FCPh MD, Chief Officer | ||
| Kyle Gutstadt, Analyst PR | ||
| Joseph Roberts, Controller | ||
| Andrew MBA, CFO Director | ||
| Joseph MSc, President, Founder | ||
| Kevin Skol, Senior Vice President - Business Development & Alliance Management | ||
| Dushyant Varshney, Chief Officer | ||
| Igor MD, Chief Officer | ||
| Neda Safarzadeh, Vice Marketing | ||
| MD MBA, Strategic Board | ||
| Natash Bowman, Chief Officer | ||
| Deepankar Roy, Director Relations | ||
| Padmanabh Chivukula, COO, Chief Scientific Officer | ||
| Keith CPA, Senior Controller |
Arcturus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcturus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 250.83 M | ||||
| Shares Outstanding | 27.09 M | ||||
| Shares Owned By Insiders | 8.45 % | ||||
| Shares Owned By Institutions | 90.17 % | ||||
| Number Of Shares Shorted | 4.48 M | ||||
| Price To Earning | 119.50 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.